Perceptual learning in speech: Stability over time (L)

Contains fulltext : 128203.pdf (publisher's version ) (Open Access)Perceptual representations of phonemes are flexible and adapt rapidly to accommodate idiosyncratic articulation in the speech of a particular talker. This letter addresses whether such adjustments remain stable over time and under exposure to other talkers. During exposure to a story, listeners learned to interpret an ambiguous sound as [f] or [s]. Perceptual adjustments measured after 12 h were as robust as those measured immediately after learning. Equivalent effects were found when listeners heard speech from other talkers in the 12 h interval, and when they had the opportunity to consolidate learning during sleep

Tracking perception of the sounds of English

Contains fulltext : 127790.pdf (publisher's version ) (Open Access)Twenty American English listeners identified gated fragments of all 2288 possible English within-word and cross-word diphones, providing a total of 538 560 phoneme categorizations. The results show orderly uptake of acoustic information in the signal and provide a view of where information about segments occurs in time. Information locus depends on each speech sound's identity and phonological features. Affricates and diphthongs have highly localized information so that listeners' perceptual accuracy rises during a confined time range. Stops and sonorants have more distributed and gradually appearing information. The identity and phonological features (e. g., vowel vs consonant) of the neighboring segment also influences when acoustic information about a segment is available. Stressed vowels are perceived significantly more accurately than unstressed vowels, but this effect is greater for lax vowels than for tense vowels or diphthongs. The dataset charts the availability of perceptual cues to segment identity across time for the full phoneme repertoire of English in all attested phonetic context

Manic Depressive Disorder (Bipolar Disorder) and its effect on the family unit

Bipolar affective disorder can mean many years of pain, confusion and loneliness for sufferers. This can also be said to be true for their families. Most relatives develop a fixed set of attitudes ranging from supportive, whatever the circumstances, to the persistently critical and hostile. It is not possible to know if the latter may be a trait or the outcome of a developmental process, but the complexity of these emotions would have some significance in the relapse, and on the family unit as a whole. This study focuses on how family members are affected by living with bipolar disorder sufferers. It is based on relative studies of schizophrenia (The Nithsdale Schizophrenia Surveys 1993, McCreadie et al). Aspects examined include: relationships, practical management, emotional support care given to relatives suffering from bipolar disorder on relative's own health, the extreme difficulty that people with the illness experience in learning from life, and the significance of stress for relatives, both financial and social. The study uses in-depth interviewing and questionnaires methodology to measure the emotions, attitudes and feelings of relatives living closely with the sufferers, and the social consequences on the family unit. The results show that the high-EE (Expressed Emotion) critical families, when the sufferers and relatives are in conflict there is a prolonged and escalating "mutual" negativity. It makes no distinction as to the originators of the negative sequence. Furthermore, in contrast to work on EE or affective style, the results indicate that in low-EE families there is an actively supportive attitude to the sufferers. This parallel is present in the study, but the findings also stress the need for the sufferers to be supporting of their carers. The cases of relapse show that the sufferers and the carers play at least an equal part in the negative inter-action associated with relapse

Pseudogap Formation in the Symmetric Anderson Lattice Model

We present self-consistent calculations for the self-energy and magnetic susceptibility of the 2D and 3D symmetric Anderson lattice Hamiltonian, in the fluctuation exchange approximation. At high temperatures, strong f-electron scattering leads to broad quasiparticle spectral functions, a reduced quasiparticle band gap, and a metallic density of states. As the temperature is lowered, the spectral functions narrow and a pseudogap forms at the characteristic temperature $T_x$ at which the width of the quasiparticle spectral function at the gap edge is comparable to the renormalized activation energy. For $T << T_x$, the pseudogap is approximately equal to the hybridization gap in the bare band structure. The opening of the pseudogap is clearly apparent in both the spin susceptibility and the compressibility.Comment: RevTeX - 14 pages and 7 figures (available on request), NRL-JA-6690-94-002

Ultrafast quasiparticle relaxation dynamics in normal metals and heavy fermion materials

We present a detailed theoretical study of the ultrafast quasiparticle relaxation dynamics observed in normal metals and heavy fermion materials with femtosecond time-resolved optical pump-probe spectroscopy. For normal metals, a nonthermal electron distribution gives rise to a temperature (T) independent electron-phonon relaxation time at low temperatures, in contrast to the T^{-3}-divergent behavior predicted by the two-temperature model. For heavy fermion compounds, we find that the blocking of electron-phonon scattering for heavy electrons within the density-of-states peak near the Fermi energy is crucial to explain the rapid increase of the electron-phonon relaxation time below the Kondo temperature. We propose the hypothesis that the slower Fermi velocity compared to the sound velocity provides a natural blocking mechanism due to energy and momentum conservation laws.Comment: 10 pages, 11 figure

Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use

Tobacco and alcohol use are leading causes of mortality that influence risk for many complex diseases and disorders 1 . They are heritable 2,3 and etiologically related 4,5 behaviors that have been resistant to gene discovery efforts 6–11 . In sample sizes up to 1.2 million individuals, we discovered 566 genetic variants in 406 loci associated with multiple stages of tobacco use (initiation, cessation, and heaviness) as well as alcohol use, with 150 loci evidencing pleiotropic association. Smoking phenotypes were positively genetically correlated with many health conditions, whereas alcohol use was negatively correlated with these conditions, such that increased genetic risk for alcohol use is associated with lower disease risk. We report evidence for the involvement of many systems in tobacco and alcohol use, including genes involved in nicotinic, dopaminergic, and glutamatergic neurotransmission. The results provide a solid starting point to evaluate the effects of these loci in model organisms and more precise substance use measures

A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial

Background Cough can be a debilitating symptom of idiopathic pulmonary fibrosis (IPF) and is difficult to treat. PA101 is a novel formulation of sodium cromoglicate delivered via a high-efficiency eFlow nebuliser that achieves significantly higher drug deposition in the lung compared with the existing formulations. We aimed to test the efficacy and safety of inhaled PA101 in patients with IPF and chronic cough and, to explore the antitussive mechanism of PA101, patients with chronic idiopathic cough (CIC) were also studied. Methods This pilot, proof-of-concept study consisted of a randomised, double-blind, placebo-controlled trial in patients with IPF and chronic cough and a parallel study of similar design in patients with CIC. Participants with IPF and chronic cough recruited from seven centres in the UK and the Netherlands were randomly assigned (1:1, using a computer-generated randomisation schedule) by site staff to receive PA101 (40 mg) or matching placebo three times a day via oral inhalation for 2 weeks, followed by a 2 week washout, and then crossed over to the other arm. Study participants, investigators, study staff, and the sponsor were masked to group assignment until all participants had completed the study. The primary efficacy endpoint was change from baseline in objective daytime cough frequency (from 24 h acoustic recording, Leicester Cough Monitor). The primary efficacy analysis included all participants who received at least one dose of study drug and had at least one post-baseline efficacy measurement. Safety analysis included all those who took at least one dose of study drug. In the second cohort, participants with CIC were randomly assigned in a study across four centres with similar design and endpoints. The study was registered with ClinicalTrials.gov (NCT02412020) and the EU Clinical Trials Register (EudraCT Number 2014-004025-40) and both cohorts are closed to new participants. Findings Between Feb 13, 2015, and Feb 2, 2016, 24 participants with IPF were randomly assigned to treatment groups. 28 participants with CIC were enrolled during the same period and 27 received study treatment. In patients with IPF, PA101 reduced daytime cough frequency by 31·1% at day 14 compared with placebo; daytime cough frequency decreased from a mean 55 (SD 55) coughs per h at baseline to 39 (29) coughs per h at day 14 following treatment with PA101, versus 51 (37) coughs per h at baseline to 52 (40) cough per h following placebo treatment (ratio of least-squares [LS] means 0·67, 95% CI 0·48–0·94, p=0·0241). By contrast, no treatment benefit for PA101 was observed in the CIC cohort; mean reduction of daytime cough frequency at day 14 for PA101 adjusted for placebo was 6·2% (ratio of LS means 1·27, 0·78–2·06, p=0·31). PA101 was well tolerated in both cohorts. The incidence of adverse events was similar between PA101 and placebo treatments, most adverse events were mild in severity, and no severe adverse events or serious adverse events were reported. Interpretation This study suggests that the mechanism of cough in IPF might be disease specific. Inhaled PA101 could be a treatment option for chronic cough in patients with IPF and warrants further investigation